Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of bevacizumab + temozolomide with concurrent radiotherapy followed by bevacizumab + temozolomide + anlotinib for primary glioblastoma
ChiCTR2400091275Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, temozolomide and anlotinib in glioblastoma (GBM), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
bevacizumabtemozolomideanlotinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2400091275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091275.